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ABSTRACT 
Objective: Ivermectin is an FDA-approved, broad-spectrum anti-parasitic agent. It was originally identified as an inhibitor of interaction between 
the human 29 immunodeficiency virus-1 (HIV-1) integrase protein (IN) and the Importin (IMP) α/β1 30 heterodimers, which are responsible for IN 
nuclear import. Recent studies demonstrate that ivermectin is worthy of further consideration as a possible SARS-CoV-2 antiviral.  
Methods: We built the pathogen-host interactome and analyzed it using PHISTO. We compared Ivermectin and plant molecules for their interaction 
with Importin α3 (IMA3) using molecular docking studies.  
Results: A phytochemical ATRI001 with the lowest binding energy-7.290 Kcal/mol was found to be superior to Ivermectin with binding energy-
4.946 Kcal/mol.  
Conclusion: ATRI001 may be a potential anti-SARS-CoV-2 agent; however, it requires clinical evaluation. 
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INTRODUCTION 
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the 
causative agent of COVID-19 pandemic, is a single-stranded positive-
sense RNA virus, which is closely related to earlier SARS-CoV [1]. 
Available reports on SARS-CoV proteins have demonstrated a poten-
tial role of IMPα/βduring infection in the signal-dependent nucleo-
cytoplasmic shutting of the SARS-CoV Nucleocapsid protein [2-5], 
that may cause significant impact on host cell division [6, 7]. Addi-
tionally, the SARS-CoV accessory protein ORF6 has been shown to 
antagonize the antiviral activity of the STAT1 transcription factor by 
sequestering IMP α/β1 on the rough ER/Golgi membrane [8]. These 
reports suggest that nuclear transport inhibitory activity of ivermec-
tin may be effective against SARS-CoV-2. 
Seven human isoforms of IMA mediate nuclear import of cargo into 
the tissue in an isoform-specific manner. Active transport of proteins 
from the cytoplasm to the nucleus is mediated by a family of nuclear 
transport receptors known as importins (or karyopherins), together 
with several ancillary proteins, including nucleoporins and Ran [8-
10]. The classical nuclear import pathway is initiated by a unique 
NLS on importin α [11]. The cargo-IMA complex gets transported 
through the nuclear pore by building a heterotrimer complex with 
importin β (IMB), necessitating interactions with FG repeat regions 
on nucleoporin proteins [12, 13].  
Once the complex traverse the nuclear envelope, the RanGTP dissoci-
ates the complex, and the import receptors get recycled back to the 
cytoplasm for the next rounds of transport [14-17]. IMA includes 
importin β-binding (IBB) domain at its N-terminal and NLS binding 
domain towards C-terminal featuring ten armadillo (ARM)-repeat 
motifs [18]. Most commonly, the cargo NLS binds on the concave site 
of the ARM repeats and involves interactions at either the major site 
through ARM repeats 2–4 or minor site ARM repeats 6–8. The classical 
monopartite NLSs (e. g., SV40T-ag [19]) are known to interact with the 
major site, while, human phospholipid scramblase [20] and TPX2 [21] 
with the minor site. The classical bipartite NLSs like nucleoplasmin 
interact with both the major and minor sites [19]. Although this pro-
cess has been well characterized for the importin α1 adaptor protein, 
many nuclear proteins exhibit specificity for other importin α 
isoforms. 
For example, both RCC1 [22], HIV-1 integrase [23], W protein of 
Nipah virus (NiV) [24, 25], avian influenza PB2 viral polymerase 
subunit [26] and SARS-CoV2 bind specifically to importin α3. 
Whereas, STAT1, a signaling molecule in the innate immune system 
response, binds specifically to the convex C-terminal surface of im-
portin α5, α6, and α7 [27, 28]. 
A wide variety of active phytochemicals have been found to have 
therapeutic applications against viruses. The antiviral mechanism of 
these agents may be explained by their antioxidant activities, scav-
enging capacities, inhibition of DNA, RNA synthesis, or blocking of 
viral reproduction. Epidemiological and experimental studies have 
revealed that a large number of phytochemicals have promising 
antiviral activities [29].  
More than 220 Phyto-compounds evaluated by others for activity 
against anti-severe acute respiratory syndrome-associated coronavirus 
(SARS-CoV) using a cell-based assay measuring the SARS-CoV-induced 
cytopathogenic effect on Vero E6 cells and compounds [30–32] showed 
excellent activities [33, 34]. The bioactive compounds with anti-SARS-
CoV activity in the mmol range included abietane and labdane-type 
diterpenes sesquiterpenes and lupane-type triterpenes [34]. 
The current study is aimed to screen a library of plant small mole-
cules library against IMA3 using molecular docking studies. The 
plant small molecule library developed in-house, consists of 
4,08,000 small molecules, which are classified using physicochemi-
cal parameters as major classifiers. 
MATERIALS AND METHODS 
Topological analysis of pathogen-host interactome (PHI) 
The drug target identification and validation were carried out using a 
network-based topological analysis method using a web-based applica-
tion Pathogen-Host Interaction Search Tool (PHISTO) available at the 
URL: http://www.phisto.org/browse.xhtml#. PHISTO is the most com-
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prehensive pathogen-human protein-protein interaction database on the 
web. It is used to explore molecular connectivities between the path-
ways in SARS-CoV and Human interaction through topological analysis 
[35, 36]. The information over the interaction of human IMA3 (Uniprot 
ID: O00629) was retrieved from PHISTO. 
Protein preparation 
The crystal structure of IMA3 was pre-processed for docking studies 
using the Protein Preparation Wizard [37] available in Schrödinger suite 
2019-2. Crystallographic water molecules (water molecules without 3 H 
bonds) were deleted and hydrogen bonds corresponding to pH 7.0 were 
added, considering the appropriate ionization states for both the acidic 
and basic amino acid residues. Missing side-chain atoms were added, 
and breaks present in the structure were built using Prime v4.0, 
Schrodinger 2019-2 [38]. Using the OPLS_2005 force field [39] energy of 
the modeled structure was minimized.  
Binding site prediction 
The crystal structure of Hendra virus W protein C-terminus in complex 
with IMA3 crystal form 2 (PDB ID: 6BWA) and IMA3 in cargo free state 
(PDB ID: 6BVZ) was superimposed to understand the conformational 
differences between cargo bound state and free state. The protein struc-
ture alignment and superimposition was performed concerning back-
bone atoms using Schrodinger package Maestro ver9.3.  
Ligand preparation 
The three-dimensional conformers of Ivermectin and 4,08,000 small 
plant molecules in our library were subjected for ligand minimiza-
tion using the Ligprip application provided in Schrödinger Maestro 
[39]. The ligand minimization was performed by assigning force 
field OPLS_2005 and stereoisomers were calculated retaining specif-
ic chiralities. The ADME (absorption, distribution, metabolism, and 
excretion) predictions were done for all ligands using the QikProp 
package (version 4.6 Schrodinger, LLC, New York, NY, 2015) [40].  
Molecular docking 
The crystal structure of human IMA3, an adaptor protein involved in 
the transport of viral protein from the cytoplasmic compartment of 
an infected cell into a nuclear compartment through NPCs, was pre-
pared using the Protein Preparation Wizard [41]. The major NLS 
binding site (137–229) was defined with a 10 Å radius around the 
selected residues (Asn141, Ser144, Trp179, Asn183, and Asn219) 
present in the crystal structure which are identified as key residues 
in SARS_nCoV-2 protein and host IMA3 complex formation and a 
grid box 20X20X20 Å was generated at the centroid of the active site 
for docking. The molecular docking of prepared small molecules 
over IMA3 was performed using Grid-Based Ligand Docking with 
Energetics Glide v7.8, Schrodinger 2019-2 [42] in ‘High Throughput 
Virtual Screening’ HTVS mode without applying any constraints. 
Considering the glide score 13,000, molecules were shortlisted and 
subjected for docking in ‘standard precision’ SP mode. The top mole-
cules with high glide score and Ivermectin were further screened 
using in ‘extra precision’ mode. The final best-docked structure was 
selected using a Glide score function, Glide energy, and Glide E mod-
el energy. Finally, the lowest-energy docked complex of three plant 
molecules and ivermectin were interpreted to derive the conclusion. 
RESULTS AND DISCUSSION 
Topological analysis of pathogen-host interactome and drug 
target identification 
A thorough analysis of virus-host interactomes may reveal insights 
into viral infection and pathogenic strategies [43, 44]. In the current 
study, IMA3 centric Virus-Human interactome was built by screen-
ing domain interactions between Virus-Human protein-protein 
interactions (PPIs), as shown in table 1. The list of human viruses, 
including SARS-CoV is reported to transport their cargo protein 
through IMA3 (Uniprot ID: O00629) mediated nuclear transporta-
tion mechanism. Due to the lack of experimental interaction data on 
SARS-CoV-2, the significant identity between SARS-CoV (Taxonomy 
ID: 227859) and SARS-CoV-2 (Taxonomy ID: 2697049) proteomes 
has encouraged us to considered and the SARS-CoV-Human interac-
tome. Through PHI analysis, it is understood that the transportation 
of SARS-CoV-2 cargo protein NS6 from the cytoplasmic compart-
ment to the nuclear compartment of the infected host cell is mediat-
ed by IMA3 [2,3]. Hence, IMA3 is identified as a potential target and 
molecular docking was performed. 
Binding site prediction 
The human IMA3 has its significant function in nuclear protein im-
port as an adapter protein for nuclear receptor KPNB1. IMA3 binds 
specifically and directly to substrates containing either a simple or 
bipartite NLS motif [45]. Docking of the importin/substrate complex 
to the nuclear pore complex (NPC) is mediated by KPNB1 through 
binding to nucleoporin FxFG repeats and the complex is subsequent-
ly translocated through the pore by an energy-requiring, Ran-
dependent mechanism. At the nucleoplasmic side of the NPC, Ran 
binds to IMB, and the three components separate to get re-exported 
from the nucleus to the cytoplasm where GTP hydrolysis releases 
Ran from importin [46]. Hence, the NLS site on IMA3 is very im-
portant in nuclear protein import.  
As tabulated in table 2, IMA3 Consists of an N-terminal hydrophilic 
region, a hydrophobic central region composed of 10 ARM repeats, 
and a short hydrophilic C-terminus. The N-terminal hydrophilic 
region contains the IBB domain, which is sufficient for binding IMB 
and essential for nuclear protein import [47]. The IBB domain is 
thought to act as an intragastric autoregulatory sequence by inter-
acting with the internal autoinhibitory NLS as shown in fig. 1. 
 
 
Fig. 1: Simplified representation of IMA3 and nuclear pore complex of cargo containing a classical NLS occurs via importin-α/importin-β 
heterodimer. As noted IMA3 has major and minor NLS binding sites specific to cargo type 
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Table 1: Interaction of human importin α3 (Uniprot_ID: O00629) with diverse pathogen proteins 
Pathogen Taxonomy ID Uniprot ID Pathogen protein Experimental method Pubmed ID 
Bovine papillomavirus TYPE 1 (BPV 1) 10559 P03116 VE1_BPV1 CIP 17192311 
Deltapapillomavirus 4 337052 P03116 VE1_BPV1 CIP 17192311 
Hendra virus ISOLATE 
HORSE/AUSTRALIA/HENDRA/1994 
928303 P0C1C6 W_HENDH TAP 22810585 
Human herpesvirus 8 37296 O40917 O40917_HHV8 Other Methods 25544563 
Human herpesvirus 8 STRAIN GK18 868565 Q2HRC8 ORF11_HHV8P ACT 25544563 





HIV1 11676 Q79822 Q79822_9HIV1 Y2H, CIP, NMR 8659115, 
9548947 
HIV1 11676 Q71B33 Q71B33_9HIV1 Y2H, CIP, NMR 8659115, 
9548947 
HIV1 11676 Q72874 Q72874_9HIV1 FT, imaging technique 10366569, 
12414950 
HIV1 11676 Q77YF8 Q77YF8_9HIV1 pull down 22174317 
HIV1 ISOLATE BRU 11686 P04620 REV_HV1BR pull down 22174317 
HIV1 ISOLATE HXB2 11706 P04618 REV_HV1H2 ACT 22174317 
HIV1 ISOLATE HXB2 11706 P04585 POL_HV1H2 ATC, pull down 20554775 
HIV1 ISOLATE HXB2 11706 P69726 VPR_HV1H2 ATC 20554775 
Influenza A virus STRAIN 
A/AICHI/2/1968 (H3N2) 
387139 I6TAH8 I6TAH8_I68A0 ATC 28169297 
Influenza A virus STRAIN A/PUERTO 
RICO/8/1934 (H1N1) 
211044 P03466 NCAP_I34A1 pull down, ATC 12740372, 
28169297 
Influenza A virus STRAIN A/PUERTO 
RICO/8/1934 (H1N1) 
211044 P03428 PB2_I34A1 ATC 28169297 
Influenza A virus STRAIN A/PUERTO 
RICO/8/1934 (H1N1) 
211044 P03433 PA_I34A1 ABC 26789921 
Influenza A virus STRAIN A/UDORN/1972 
(H3N2) 
385599 Q20MD0 Q20MD0_9INFA Other Methods 17376915 
Influenza A virus STRAIN 
A/VICTORIA/3/1975 (H3N2) 




Influenza A virus STRAIN A/Wilson-
Smith/1933 (H1N1) 
381518 P03427 PB2_I33A0 CIP 25464832 
Influenza A virus STRAIN A/Wilson-
Smith/1933 (H1N1) 
381518 P15682 NCAP_I33A0 CIP 25464832 
Influenza A virus STRAIN A/Wilson-
Smith/1933 (H1N1) 
381518 P03470 NRAM_I33A0 CIP 25464832 
Influenza A virus STRAIN A/Wilson-
Smith/1933 (H1N1) 
381518 B4URF7 B4URF7_9INFA ACT, ATC 26651948, 
28169297 
JC polyomavirus 10632 Q9DUG7 Q9DUG7_POVJC TAP 22810586 
Macaca mulatta polyomavirus 1 1891767 P03070 LT_SV40 ELISA, TAP, pull down 9168958, 
22810586, 
20701745 
Macaca mulatta polyomavirus 1 1891767 Q9DH70 Q9DH70_SV40  Y2H 9168958, 
12740372 
Merkel cell polyomavirus 493803 B8ZX42 B8ZX42_9POLY TAP 22810586 
Murid herpesvirus 4 (Murine herpesvirus 
68) 
33708 O41946 O41946_MHV68  22028648 
Nipah virus 121791 Q997F2 V_NIPAV TAP 22810585 
Nipah virus 121791 P0C1C7 W_NIPAV TAP 22810585 
Plasmodium yoelii yoelii 73239 P06914 CSP_PLAYO pull down 17981117 
Severe acute respiratory syndrome 
(SARS) coronavirus 
227859 P59634 NS6_CVHSA Y2H 17596301 
Yersinia pestis 632 Q8D1P8 Q8D1P8_YERPE Y2H, Pooling approach 20711500 
 
Table 2: List of molecular features and functional sites on human IMA3 
Feature key Description Position(s) on O00629 
Domain IBB 2–58 
Repeat ARM 1, Truncated 66–106 
Repeat ARM 2 107–149 
Repeat ARM 3 150–194 
Repeat ARM 4 195–233 
Repeat ARM 5 234–278 
Repeat ARM 6 279–318 
Repeat ARM 7 319–360 
Repeat ARM 8 361–400 
Repeat ARM 9 401–443 
Repeat ARM 10; Atypical 447–485 
Region NLS binding site (major) 137–229 
Region NLS binding site (minor) 306–394 
Motif Nuclear localization signal 43–52 
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Binding of KPNB1 probably overlaps the internal NLS and contrib-
utes to a high affinity for cytoplasmic NLS-containing cargo sub-
strates [48]. After dissociation of the importin/substrate complex in 
the nucleus the internal autoinhibitory NLS contributes to a low 
affinity for nuclear NLS-containing proteins. The major and minor 
NLS binding sites are mainly involved in recognition of simple or 
bipartite NLS motifs. As described by Elena et al., in 1998 [49], struc-
turally located within a helical surface groove, they contain several 
conserved Trp and Asn residues of the corresponding third helices 
(H3) of ARM repeats which mainly contribute to binding as shown in 
fig. 1. The secondary structure superimposition of the two IMA3 
structures in cargo bounded and Free State reveals a global root-
mean-square deviation (RMSD) of 1.27 Å. And the major RMSD con-
tribution was observed at the ARM2-3 position because of the re-
markable conformational change in the loop at the NLS site, as 
shown in fig. 2A-2C. Hence the amino acids at the ARM2-3 region 
(Asn141, Ser144, Trp179, Asn183, and Asn219) were identified as a 
key binding site residue. 
 
 
Fig. 2: A: The crystal structure of IMA3 in cargo free state with an open loop at the NLS Major Site (PDB ID: 6BVZ). B: The crystal structure 
of Hendra virus W protein C-terminus (the loop in golden color) in complex with IMA3 crystal form 2 rendering closed loop at NLS Major 







Fig. 3: Molecular interaction of ligands with at NLS major binding site on human IMA3 (PDB ID: 6BWA). A: Two-Dimensional (2D) repre-
sentation of ATRI001 interaction with IMA3 facilitated by 6 H-bonds shown in pink arrow. B: Three dimensional (3D) illustration of 
ATRI001 interaction with IMA3 facilitated by 6 H-bonds shown in yellow dotted lines. C: Three dimensional (3D) illustration of Ivermec-
tin interaction with IMA3 facilitated phobic enclosures but no H-Bonds 
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The molecular docking study was performed to understand the 
molecular interaction of plant molecules with human IMA3. Initial 
HTVS screening suggested 13,000 molecules with reasonable inter-
action with IMA3, and further, the shortlisted molecules were 
docked in the standard precision mode where the accuracy of pre-
diction is better than the HTVS mode [50].  
The docking in SP mode has suggested 20 top molecules as lead mole-
cules. As ivermectin is reported to inhibit IMA3 mediated cargo nuclear 
import, it was also subjected to subsequent docking in extra precision 
(XP) mode. All 20 plant molecules showed better interaction than iver-
mectin with IMA3. However, the lowest energy ligand-bound conform-
ers are always energetically favorable [51]. Hence, the plant molecule 
ATRI001 with the lowest binding energy-7.290 Kcal/mol was identified 
as a potent inhibitor of IMA3 by displaying better interactions with NLS 
site on human IMA3 by forming 6 H-bonds with Asp102, Asn141, 
Ser144, Trp179, Asn183 and Asn219 as shown in fig. 3A and 3B. 
ATRI001 is a glycoconjugate having (2R,3R,4S,5S,6R)-6-Ethyloxane-
2,3,4,5-tetrol as a monosaccharide sugar group and connected to 
phyto-moiety (1R,2R,4S)-1-[(3R)-3-Hydroxybut-1-enyl]-2,6,6-
trimethylcyclohexane-1,2,4-triol through glycosidic linkage. The 
interaction of sugar group with IMA3 is facilitated by 3 H-bonds, two 
of them were formed by donating electrons to side-chain atoms of 
Asn141 and Ser144, one of 3 H-bonds was formed by accepting the 
electron from backbone atoms of Asp102. Whereas interaction be-
tween photo-moiety and IMA3 was established by means of 3 H-
bonds, two of them were formed by donating electrons to side-chain 
atoms of Asn183 and Asn219, remaining H-bond found formed by 
accepting the electron from backbone atoms of Asp102. Ivermectin, 
a known IMA3 inhibitor, showed its lowest biding energy-4.946 
Kcal/mol at its lowest energy conformation without any hydrogen 
bonds, as shown in fig. 3C. Hence, the interaction of ATRI001 was 
found better than ivermectin by using three parameters: fitting at 
NLS binding site, low interaction penalties, and a good number of 
bonded interactions. 
CONCLUSION 
The Comparative analysis to evaluate the IMA3 inhibition activity of 
Ivermectin and plant small molecules using in silico approaches 
suggested that a plant molecule ATRI001 is superior to Ivermectin. 
Our in silico experiment shows ATRI001 can block the nuclear im-
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